Gilead Sciences (Australia)

Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal – A modeling approach

AIM: This study aimed to quantify the health benefits that can be achieved by treating axicabtagene-ciloleucel (axi-cel)-eligible large B-cell lymphoma patients with axi-cel instead of historical standard of care (hSoC) in Portugal. "Estimated Opportunity Lost" quantified the dif...